| Prev Close | 68.72 |
| Day Low/High | 65.77 / 68.62 |
| 52 Wk Low/High | 13.53 / 95.21 |
Moderna, Inc. (MRNA)
67.16
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 394.59B |
| Market Cap | 27.12B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Stock-Specific Ideas for the Post-Fed Era of Investing
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
How About That Merck and Seattle Genetics Deal?
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Challenging Markets, Nvidia Acquires Arm, Oracle Wins TikTok, Vaccine Update
Also, several scheduled events this week, election risk, earnings to watch.
My Vaccine Bet Remains on Pfizer for a Disease I Don't Wish on Anyone
This writer is rooting for the success of all efforts to halt the spread of the virus as he struggles with the aftereffects of the disease.
Moderna and AstraZeneca Could Use a Shot in the Arm
An effective Covid-19 will be a game-changer, but charts say the bottom-line impact may not be as significant as previously believed.
Waves of Buying, Above-Average Indices, Vaccine Mania: Market Recon
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
Vaccine Chills, Divergent Trails, Fed-flation, Walmart and TikTok: Market Recon
Plus, Veeva Systems reports stellar results and ups its guidance.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Apple Still King, Dow Shell Game, More Market Faith, Renewed China Talks?
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
Mitch's Hurtful Words, Tuesday's Tumble, Do-Nothing Congress: Market Recon
Plus, quick looks at Joe Biden's VP choice, the latest on the Covid-19 vaccine front and Tesla's stock split.
The Rally Broadens, Dow Theory, Virus Cocktail, 4 Questions: Market Recon
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
Jim Cramer: Betting Against Science Is a Mug's Game
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
Jim Cramer: Clorox, Covid and Indecision on Packaged Goods Stocks
The whole group has run and the guidance from Clorox does show, more than anything, that nobody knows.
Ozzy and I Don't Know, Hare-Raising Tale, Enter the Dog Days: Market Recon
Plus, Russia could provide a real-time clinical trial of a coronavirus vaccine.
Jim Cramer: I'm Sick of Hearing All This Nonsense About the Fed
Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.
Jim Cramer: Here Are My Top 10 Pandemic Paradox Stocks
In a 'normal' recession, these would be real losers -- but right now? They look like numero 'UNO'.
Danger Beneath the Waves, Chip Stocks Ahoy, Fiscal Battle, Sizing Up Starbucks
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Caution Signs, Laboring Labor Market, Gold Watch and Ugly Intel: Market Recon
Plus, why shares of vaccine maker Moderna are taking a hit.
A Complete Review of the Past Week's Macroeconomic Developments
Here is a summary of this week's major macroeconomic events: The Positives 1) Moderna , while still having to progress thru phase 3 trials, reported positive antibody results from phase 1 data and brings us a step closer to that hoped for vaccine....
Jim Cramer: An Analyst's Dream
All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.
Small Caps Make Some Big Noise
FAANG stocks lag while the Russell rises, bringing divergences and questions.
Treasury Yields Post-Covid, Reading Fed Tea Leaves and Junk Bond Intrigue
A Fed governor speaks of accommodation, and AMC Entertainment's bond maneuvers serve as a warning to those who swim in the high-yield pool.
The Only Certainty Is the Lack of Certainty
* Much like the Wild West, the market's action has turned unpredictable and volatile -- with little of a thematic character, save trading within a defined range and with some outstanding (and speculative) characters. The encouraging announcement of ...
An Ugly Intraday Reversal Turns Into a Bear Trap
Stock picking continues to be the most productive approach as market timers are battered and bruised once again.
Jim Cramer: How Do You Refute These Market Gains?
This is pretty much exactly what you get when you have so much positive research.
